2022 Rheumatology Competitive Grant Program

Funding Agency:
Pfizer Inc.

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

The intent of this Request for Proposal (RFP) is to support both clinical and basic science research on the pathogenesis and treatment of Rheumatology conditions through a competitive grant program with the intent to increase medical knowledge of the following areas:

Rheumatoid Arthritis

  • Risk assessment of MACE, Mortality, and Malignancy in Rheumatoid Arthritis and related inflammatory arthropathies.
  • Diagnosis and management of extra-articular manifestations of RA (ex: lung, heart, kidney, skin, etc.)
  • Developing predictive models to identify patients with high risk of development of inflammatory arthritis.

Spondyloarthritis (SpA)

  • Understanding the relationship between the gut microbiome and factors associated with early onset of spondyloarthritis and IBD.
  • Innovative models of referrals to Rheumatology for SpA to improve diagnosis time, and multidisciplinary care teams.
  • The role of JAK/STAT inhibition for different subtypes of SpA (ex: raxSpA, nr-axSpA, pSpA, uSpA, extra-articular manifestations).
  • Explain characteristics of patients with uveitis and recurrent uveitis amongst different subtypes of SpA.

Juvenile Idiopathic Arthritis (JIA)

  • Clinical, genomic, and or biomarker profiles to predict treatment response in JIA.
  • Improved diagnosis and management of temporomandibular joint (TMJ) disorders in childhood inflammatory arthropathies.

Other Rheumatic Diseases

  • The role of JAK/STAT pathway in the pathogenesis of Systemic Lupus Erythematosus, Idiopathic and Inflammatory Myopathies, or Systemic Sclerosis.
  • The role of JAK/STAT in Polymyalgia Rheumatica and Giant Cell Arteritis including factors leading to progression, and management.


  • Non pharmaceutical interventions for rheumatic diseases: herbal and complementary therapy, dietary changes, psycho-social interventions, and exercise programs.
  • Precision medicine to determine response to therapy (ex: biometrics, biomarkers, genomics, etc.).
  • Research in Diversity, Equality, and Inclusion: race-conscious approaches and inclusiveness of underrepresented patient populations to assess and address healthcare disparities.


  • Evaluating the utility of remote monitoring of Rheumatic patients including diagnosis, disease management, or clinical trial enrollment.
  • AI and Machine learning in Rheumatology for classification, diagnosis, treatment.
  • Understanding the role of social media platforms for medical learning, networking, collaboration, and research

Full Proposal Deadline: February 8, 2022

Agency Website

Eligibility Requirements

Geographic Scope • United States

To be eligible:

  • The institution and principal investigator (PI) must be based in one of the eligible countries noted above.
  • Only organizations are eligible to receive grants, not individuals or medical practice groups.
  • The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
  • Applicant must be affiliated with a host institution
  • Both early career and experienced investigators are encouraged to apply, and consideration will be given to all proposals meeting the selection criteria



Amount Description

Individual projects requesting up to $150,000 will be considered.

Funding Type





Medical - Basic Science
Medical - Clinical Science

External Deadline

February 8, 2022